Hims & Hers Health (NYSE:HIMS) Director David Wells Buys 48,400 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) Director David Wells bought 48,400 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was purchased at an average price of $24.23 per share, for a total transaction of $1,172,732.00. Following the purchase, the director directly owned 224,417 shares in the company, valued at approximately $5,437,623.91. This represents a 27.50% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Hims & Hers Health Trading Up 0.2%

NYSE HIMS opened at $23.79 on Wednesday. The stock has a market capitalization of $5.51 billion, a price-to-earnings ratio of -264.33, a PEG ratio of 46.09 and a beta of 2.43. The stock’s 50 day moving average price is $24.01 and its two-hundred day moving average price is $27.71. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. During the same quarter in the prior year, the company earned $0.20 EPS. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. Flagship Harbor Advisors LLC acquired a new position in Hims & Hers Health in the 4th quarter valued at $28,000. Binnacle Investments Inc acquired a new position in Hims & Hers Health in the 3rd quarter valued at $28,000. Bogart Wealth LLC grew its holdings in Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after buying an additional 632 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health in the 1st quarter valued at $30,000. Finally, Greenline Wealth Management LLC acquired a new position in Hims & Hers Health in the 4th quarter valued at $36,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Needham & Company LLC upped their price objective on Hims & Hers Health from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. BTIG Research reiterated a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Truist Financial upped their price objective on Hims & Hers Health from $18.00 to $23.00 and gave the stock a “hold” rating in a research note on Friday, May 22nd. Weiss Ratings cut Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th. Finally, Jefferies Financial Group set a $24.50 price objective on Hims & Hers Health in a research note on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.70.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.